Latest news

CEO Comment Q2 2024

5 July, 2024

We have now produced a number of consecutive large-scale batches within specifications which has enabled us to build up a stock of products for sale. We have also received our first slightly larger order for NLAB Saga® and we are now intensifying our sales efforts. It is very gratifying that the systematic work to further develop the large-scale production of our silica media NLAB Saga® has borne fruit – the plant now delivers significantly larger

Nanologica Receives Order for NLAB Saga of approx SEK 2 Million

20 June, 2024

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million. The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production. “In China, we see a very strong activity in the GLP-1 analogue segment as a result of the patent for

The Production of NLAB Saga® Stabilizes

18 June, 2024

Nanologica has now approved a number of normal-sized batches from the large-scale production of the company’s silica for preparative chromatography, NLAB Saga®. Scaling up to large-scale production of silica at the contract manufacturer Sterling Pharma Solutions has been fraught with several challenges such as loss of material, which has previously been communicated. Although a couple of challenges remain, the company has now for the first time completed several large production batches in a row, which

Presentation from Redeye Diabetes Event – 23 May 2024

24 May, 2024

Watch the presentation via the link: CEO Andreas Bhagwani presents at Redeye Diabetes Event – 23 May 2024

Nanologica presents at Redeye Theme: Diabetes 23 May

22 May, 2024

Nanologica’s CEO Andreas Bhagwani will present the company at Redeye Theme: Diabetes on 23 May at 11.10. Link to follow the event

Bulletin from the AGM in Nanologica

16 May, 2024

Nanologica AB (publ) today 16 May 2024 held its Annual General Meeting in Stockholm, at which the following resolutions were adopted. Adoption of the income statement and balance sheet, disposition of result The Annual General Meeting adopted the income statement and balance sheet for the company and the group in accordance with the presented accounting documents and resolved, in accordance with the board´s proposal, that the accumulated loss of SEK -75,880,232 shall be carried forward.

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Categories

News archive